Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 31:argenx SE (ARGX) : This biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 56.2% over the last 60 days.argenx's shares gained 32.9% over the last three months compared with the S&P 500’s advanced of 8.4%. The company possesses a Momentum Score of A.Vizsla Silver Corp. (VZLA) : This mineral exploration company has a Zacks R ...

argenex SE (ARGX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a cha ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. argenex SE (ARGX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.argenex SE is a member of the Medical sector. This group includes 1024 individual stocks and currently holds a Zacks Sector Rank of #4. The Zac ...

argenx SE (NASDAQ:ARGX) Q2 2024 Earnings Conference Call July 25, 2024 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Global Head of Corporate Communications & Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants James Gordon - JPMorgan Tazeen Ahmad - Bank of America Allison Bratzel - Piper Sandler Rajan Sharma - Goldman Sachs Derek Archila - Wells Fargo Akash Tewari - Jef ...

| --- | --- | --- | --- | --- | --- | --- | |-------|---------|-------|----------------------------------------------------|----------------------------|-------|-------| | | | | | | | | | | | | | | | | | Q 2 | 202 4 | | Reaching Patients through E A R N I N G S C A L L | \| J u l y 2 5 , 2 0 2 4 | | | | | | | Immunology Innovation | | | | | | | | | | | | Forward Looking Statements 2 This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any o ...

Core Insights - argenx SE reported global net product sales of $478 million in the second quarter of 2024, a significant increase from $269 million in the same period of 2023 [6][13] - The company launched VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP) in the U.S. following FDA approval on June 21, 2024 [5][6] - argenx aims to achieve its Vision 2030 goals, which include treating 50,000 patients globally and obtaining 10 labeled indications across its approved assets [4][22] Financial Performance - Total operating income for the second quarter of 2024 was $489 million, compared to $281 million in the same period of 2023 [11][13] - Research and development expenses increased to $225 million in Q2 2024 from $196 million in Q2 2023, reflecting ongoing investment in clinical development [12][13] - The company reported a profit of $29 million for the second quarter of 2024, a turnaround from a loss of $94 million in the same period of 2023 [16] Product Development and Pipeline - argenx is on track to initiate four additional registrational studies for efgartigimod and empasiprubart by the end of 2024 [3][22] - The company is advancing its pipeline with multiple candidates, including efgartigimod in 15 indications and empasiprubart for various autoimmune diseases [8][9] - A registrational study for VYVGART in ocular myasthenia gravis is expected to start by the end of 2024 [6][9] Regulatory Approvals and Market Expansion - VYVGART SC received approval for generalized myasthenia gravis (gMG) in China, with additional regulatory decisions expected in Switzerland, Australia, and Saudi Arabia in 2024 [6][13] - The company plans to file for regulatory approval of VYVGART SC in Canada by the end of 2024 [6][9] - Ongoing regulatory submissions for CIDP are under review in China, Japan, and Europe, with decisions anticipated in 2025 [6][9] Strategic Vision - The Vision 2030 plan includes a commitment to innovation in autoimmune disease treatment and aims to solidify argenx's leadership in FcRn biology [4][22] - The company is focused on expanding its patient reach and enhancing its product offerings through label expansions and new formulations [3][4] - argenx is investing in its Immunology Innovation Program to support the development of five new molecules in Phase 3 by 2030 [10][22]

July 18, 2024Amsterdam, the Netherlands – argenx ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 25, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its half year 2024 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argen ...

July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 25, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its half year 2024 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.co ...

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study July 16, 2024 6:30am CET Amsterdam, the Netherlands— argenx SE ((Euronext &amp, NASDAQ:ARGX) and Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that China's National Medical Products Administration (NMPA) approved the Biologics License Application (BLA) on July 16, 2024 for efgartigimo ...

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), which is FDA approved for use in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) June 25, 2024 – 4:30pm EDT Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committe ...